Abstract

Occurrences of high values in patients with benign prostate disease and low values in patients with highly suspicious cancer have diminished the trustworthiness of prostate‐specific antigen as an early diagnostic marker of prostate cancer. In the search for other complimentary markers, we focused on serum IgG from patients with prostate diseases as well as normal subjects. IgG purified from the sera of normal control subjects and patients with prostate diseases, was digested with peptide N‐glycanase. Released glycans were quantified using MALDI‐time of flight mass spectrometry. We report that N‐linked (N‐acetylhexosamine)2(deoxyhexose)(mannose)3(N‐acetylglucosamine)2 was significantly increased in the IgG heavy chains of patients with prostate cancer compared with that of either benign prostatic disease patients or healthy subjects, whereas (hexose)(N‐acetylhexosamine)2(deoxyhexose)(mannose)3 (N‐acetylglucosamine)2 was more abundant in the heavy chains of healthy subjects and benign prostatic disease patients. Thus, an absence of the terminal hexose of N‐linked glycans has been closely connected to the progression of prostate cancer. Furthermore, surface plasmon resonance analyses have revealed that IgG from patients with prostate cancer has a decreased binding for Sambucus nigra lectin, compared with that from the benign prostatic disease patients or from normal subjects, suggesting lower levels of (N‐acetylneuraminic acid)(α2‐6)galactose/N‐acetylgalactosamine groups in the N‐linked glycans of patient IgG. Meanwhile, wheat germ agglutinin binding to IgG of the cancer group was significantly larger than that for the benign prostatic disease group but smaller than that for normal subjects. Our study indicates that the glycosylation changes in IgG can become useful diagnostic parameters for prostate cancer.

Highlights

  • Cancer-­associated chronic inflammation upregulates the production of inflammatory cytokines, such as (IL, interleukin) IL-6­, TNF-α­, and IL-­1β [1]

  • We focused on the glycosylation status of IgG in patients with prostate cancer compared with that in benign prostatic disease (BPD) patients and in normal healthy subjects using mass spectrometry and surface plasmon resonance (SPR) analysis

  • We randomly chose the sera from 17 patients with prostate cancer, 17 patients with BPD, and five healthy subjects and determined serum cytokines using Luminex 200 multiplex assay

Read more

Summary

Introduction

Cancer-­associated chronic inflammation upregulates the production of inflammatory cytokines, such as (IL, interleukin) IL-6­, TNF-α­ (tumor necrosis factor,TNF), and IL-­1β [1]. Acute phase proteins are a group of plasma proteins, many of which are glycosylated Another consequence is the altered and/or hyperactive glycosylation of tissue plasma membrane proteins and proteins that are secreted from malignant tissues [6,7,8]. These two effects frequently occur simultaneously and many studies have reported cancer-­ associated changes in the glycosylation of APPs. It should be noted that depending on the regions or tissues where cancer develops, diverse types of glycosylation of serum proteins could occur. Many clinics have established carbohydrate antigens such as CA125, CA19-9­ , CEA, and Her2/neu as cancer biomarkers [7,8,9,10,11]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call